PTEN and neoplasm: In a phase 1 dose escalation trial examining BRCA mutations and sporadic prostate cancer patients treated with a next generation PARPi niraparib, stabilization of the disease occurred in 43% of patients; however, no correlation was observed between PTEN loss and anti-tumor activity [89].